>

NOVO-B Stock Today

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>NOV</div>
Novo Nordisk has 50 percent ods of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 30 days. Equity ratings for Novo Nordisk B AS are calculated based on the Macroaxis scoring framework. The performance scores are derived for the period starting the 5th of January 2020 and ending today, the 4th of April 2020. Click here to learn more.
Analyze Filter   Check how we calculate scores
Novo Nordisk B AS cannot be verified against its exchange. Apparently, Novo Nordisk is not available for investing at the moment. Please verify the symbol is currently traded on Copenhagen Stock Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Novo Nordisk Profile

Novo Nordisk AS, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk operates under Pharmaceuticals And Biosciences classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 42453 people.. The public information regarding Novo Nordisk B AS's current market price is not available at this time.
Legal NameNovo Nordisk B AS
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
Novo Nordisk B AS (NOVO-B) is traded on Copenhagen Stock Exchange in Denmark and employs 42,453 people. The company currently falls under 'Mega-Cap' category with current market capitalization of 779.65 B. Novo Nordisk B operates under Healthcare sector and is part of Biotechnology industry. The entity has 1.9 B outstanding shares. NOVO NORDISK -B- has accumulated about 9.05 B in cash with 44.69 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.79.
Check Novo Nordisk Probability Of Bankruptcy

NOVO-B Stock Top Holders

NOVO-B Stock Against Markets

Novo Nordisk B AS cannot be verified against its exchange. Apparently, Novo Nordisk is not available for investing at the moment. Please verify the symbol is currently traded on Copenhagen Stock Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Try Other Stock Suggestions

Check out Stocks Correlation. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page